Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Hashimoto

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Chemmedchem|August 8, 2006
Selective indole-based ECE inhibitors: synthesis and pharmacological evaluationMichael Brands, Jens-Kerim Ergüden, Kentaro Hashimoto, et al.
Molecular Oncology|July 16, 2021
Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitisToshiharu Sakurai, Marco A De Velasco, Kazuko Sakai, et al.
Molecular and Clinical Oncology|August 8, 2017
Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case reportYuto Yasuda, Yasuyo Nishikawa, Yuichi Sakamori, et al.
Annals of Clinical and Translational Neurology|March 9, 2026
Clinical Validation of Plasma p-217tau in Neurological DiseasesTakeshi Kawarabayashi, Takumi Nakamura, Ryoma Takahashi, et al.
Molecular and Clinical Oncology|July 28, 2025
Durvalumab consolidation after chemoradiotherapy for locoregional recurrent non-small cell lung cancerKeiichiro Suminaga, Hironori Yoshida, Yusuke Shima, et al.
Cancer Science|October 26, 2022
Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancerMasatoshi Yamazoe, Hiroaki Ozasa, Takahiro Tsuji, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
Clinical ManifestationsTakeshi Kawarabayashi, Takumi Nakamura, Shin Takatama, et al.
Oncology Letters|August 7, 2023
<i>CD47</i> polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancerTatsuya Ogimoto, Hiroaki Ozasa, Hironori Yoshida, et al.
Molecular Cancer Therapeutics|December 18, 2012
Antitumor activity and pharmacodynamic biomarkers of a novel and orally available small-molecule antagonist of inhibitor of apoptosis proteinsHiroyuki Sumi, Masato Yabuki, Kenichi Iwai, et al.
Bioorganic & Medicinal Chemistry|August 10, 2013
Design, stereoselective synthesis, and biological evaluation of novel tri-cyclic compounds as inhibitor of apoptosis proteins (IAP) antagonistsMoriteru Asano, Kentaro Hashimoto, Bunnai Saito, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Chemmedchem|August 8, 2006
Selective indole-based ECE inhibitors: synthesis and pharmacological evaluationMichael Brands, Jens-Kerim Ergüden, Kentaro Hashimoto, et al.
Molecular Oncology|July 16, 2021
Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitisToshiharu Sakurai, Marco A De Velasco, Kazuko Sakai, et al.
Molecular and Clinical Oncology|August 8, 2017
Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case reportYuto Yasuda, Yasuyo Nishikawa, Yuichi Sakamori, et al.
Annals of Clinical and Translational Neurology|March 9, 2026
Clinical Validation of Plasma p-217tau in Neurological DiseasesTakeshi Kawarabayashi, Takumi Nakamura, Ryoma Takahashi, et al.
Molecular and Clinical Oncology|July 28, 2025
Durvalumab consolidation after chemoradiotherapy for locoregional recurrent non-small cell lung cancerKeiichiro Suminaga, Hironori Yoshida, Yusuke Shima, et al.
Cancer Science|October 26, 2022
Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancerMasatoshi Yamazoe, Hiroaki Ozasa, Takahiro Tsuji, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
Clinical ManifestationsTakeshi Kawarabayashi, Takumi Nakamura, Shin Takatama, et al.
Oncology Letters|August 7, 2023
<i>CD47</i> polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancerTatsuya Ogimoto, Hiroaki Ozasa, Hironori Yoshida, et al.
Molecular Cancer Therapeutics|December 18, 2012
Antitumor activity and pharmacodynamic biomarkers of a novel and orally available small-molecule antagonist of inhibitor of apoptosis proteinsHiroyuki Sumi, Masato Yabuki, Kenichi Iwai, et al.
Bioorganic & Medicinal Chemistry|August 10, 2013
Design, stereoselective synthesis, and biological evaluation of novel tri-cyclic compounds as inhibitor of apoptosis proteins (IAP) antagonistsMoriteru Asano, Kentaro Hashimoto, Bunnai Saito, et al.
Pageof 5